Executive Director, Clinical Development
Zentalis
Sam Misir is Executive Director, Clinical Development Zentalis Pharmaceuticals is responsible for developing and executing clinical studies for the wee1 inhibitor ZN-c3. Sam has over19 years of experience working in the Pharma/Biotech industries. In his early career, Sam worked at Johnson & Johnson - Ortho Biotech in Medical Information and over his career has assumed positions of increasing responsibilities, including as an MSL with Procter & Gamble, Director with Daiichi Sankyo Oncology, and Sr. Medical Director and Global Medical Lead at Eisai Oncology. Most recently, Sam focused on GU oncology as Head of Medical Strategy and Operations with Ferring Pharmaceuticals and Sr. Medical Director at UroGen Pharma. Sam holds a bachelor’s degree in Pharmacy from Long Island University, Arnold & Marie Schwartz College of Pharmacy, a Doctorate in Pharmacy (PharmD) from Nova Southeastern University, and a Master’s in Business Administration from Indiana University, Kelley School of Business.
Sam Misir, PharmD, MBA